predicted that a greater number of diabetic patients will suffer from this complication than in the past. Prevention of the occurrence of this complication will become increasingly important not only for the quality of life in aged patients with diabetes, but also for the sociomedical aspects of all humanbeings.
Prevalence of diabetic osteopenia
Since 1948 when Albright (1) first pointed out abnormalities of bone metabolism in diabetes mellitus, there have been conflicting reports concerning the prevalence of this complication. Various results have been obtained according to differences in race, sex, type of diabetes, and methods used for measurement. To evaluate the prevalence of diabetic osteopenia in Japan, a nation-wide survey was conducted using microdensitometry of the second metacarpal bone (2). Of approximately ten thousand cases, 20.1 %of diabetic patients were found to have osteopenia, whereas the prevalence in the agematched controls was only 7.9% (p<0.01).
2. Pathophysiological aspects of diabetic osteopenia Bone f-carboxyglutamic acid-containing protein (BGP) is known to be one of the major noncollagenous proteins in bone matrix, and its plasma levels have been found to be a sensitive indicator of bone turnover. In addition, plasma levels of BGPwere also found to be reduced in NIDDM model rats with hyperinsulinemia. In Wistar fatty rats, plasma BGP was 47.2± 4.7 ng/ml, significantly lower than the value of 100.8±5.4 in their lean littermates (p<0.01). Bone BGPcontent also was significantly decreased in Wistar fatty rats (p<0.01). It seems likely, therefore, that impaired bone turnover is a common characteristic of diabetic osteopenia in both IDDMand NIDDM. Circulating levels of BGPand the severity of diabetic osteopenia were assessed simultaneously in clinically proven NIDDMpatients. Plasma BGP in NIDDMof both sexes was 3.9±0.3 ng/ml, which was significantly decreased compared to the values of 6.9±0.2 and 8.5 ±0.3 in age-matched controls of males and females, respectively (p<0.01). This evidence shows clearly that bone turnover is decreased in humandiabetic subjects similarly to that in diabetic animals. Since plasma BGPis found to be already reduced in patients without osteopenia and since this protein has been suggested to be involved in the process of bone mineralization (5), the decreased BGPmight contribute to the pathogenesis of diabetic osteopenia. On the other hand, it has been shown that serum BGPlevels are elevated in postmenopausal osteoporosis (6), and our study using microdensitometry revealed that the densitometer pattern of diabetic osteopenia differs in several ways from that of osteoporosis. It seems likely, therefore, that diabetic osteopenia is a different clinical entity from osteoporosis.
3. Etiology of diabetic osteopenia It was shown in a nation-wide survey that there is a negative correlation between the meandaily sunlight energy and the prevalence of diabetic osteopenia (7). This suggests that an altered vitamin D metabolism is a causative factor in diabetic osteopenia. The plasma levels of vitamin D metabolites were, therefore, measured in diabetic patients (8) .
In Prevention of diabetic retinopathy by aldose reductase inhibitor in fructose-fed diabetic rats Streptozotocin diabetic rats and normal rats were maintained from 1 to 8 months on a 72%fructose diet and treated with aldose reductase (AR) inhibitor (ONO-2235: 50 mg/kg/day) as mentioned previously (7, 14).
Effect offructose feeding and AR inhibitor on the electroretinogram (ER G)
Streptozotocin-diabetic rats were maintained on a 72%fructose diet for 4 wk and some were treated with an ARinhibitor. Prolongation of the peak latencies of the oscillatory potentials in the b-wave of the ERGwas observed in both the laboratory chow-fed and the fructose-fed diabetic rats, and tended to persist more in the fructose-fed diabetic rats than in the laboratory chow-fed diabetic rats. This prolongation of peak latencies observed in 03 and 2(0j + 02+ 03 + 04) from either the fructose-fed or the laboratory chow-fed diabetic rats was significantly reversed upon treatment with ONO-2235. Histological and biochemical observations
In the results of the examination of trypsin digestion after a 7-8 month experimental period, the changes were more severe in fructose-fed diabetic rats. In fructose-fed diabetic rats, there was a
